Tumor necrosis factor-α (TNF-α) antagonists are effective against both Blau syndrome and Takayasu arteritis [36] and TNF-α is also a significant inflammatory factor in the NF-κB signaling pathway. Here, NFKB1 is linked to Blau syndrome.